Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation

Abstract

Fixed oral doses of ximelagatran up to 60 mg twice daily were well tolerated, without the need for dose adjustment or coagulation monitoring.

Thrombomodulin and Tissue Factor Pathway Inhibitor in Endocardium of Rapidly Paced Rat Atria

“…When the inherent anticoagulant factors TM and TFPI are lost on the internal surface of the atrium, supplementation of these anticoagulant molecules or their substitutes, including thrombin inhibitors, would be promising. 13 These considerations will be assessed by the ongoing large clinical trials using a thrombin inhibtor …”

Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation

“…On the basis of the results of a previous warfarin-controlled study of ximelagatran in patients with NVAF, 14 it was estimated that the incidence of bleeding events in the warfarin group would be 15%. Based on the assumption of a similar incidence of bleeding events with edoxaban, sample size was estimated to require 104 patients to achieve a 95% confidence interval (CI) divided by 2 for the intergroup difference determined using the Score method.…”

Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety

“…Although clinical trials showed that ximelagatran, the first oral direct thrombin inhibitor to be developed, is an effective anticoagulant for many clinical indications [19][20][21][22], it was withdrawn from the market by the manufacturer in February 2006 [23] because of fears of liver toxicity. There are, however, other direct thrombin inhibitors that are under development and will appear in its wake.…”